Antibiotice Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Antibiotice.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Pharmaceuticals earnings growth	15.8%
Revenue growth rate	n/a
Future return on equity	n/a
Analyst coverage	None
Last updated	n/a

Recent future growth updates

No updates

Recent updates

Market Might Still Lack Some Conviction On Antibiotice S.A. (BVB:ATB) Even After 25% Share Price Boost

Jun 07

Are Antibiotice's (BVB:ATB) Statutory Earnings A Good Guide To Its Underlying Profitability?

Dec 16

Is Antibiotice (BVB:ATB) Using Too Much Debt?

Nov 24

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Antibiotice has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

BVB:ATB - Analysts future estimates and past financials data (RON Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
6/30/2024	651	93	36	161	N/A
3/31/2024	619	96	26	128	N/A
12/31/2023	615	81	24	122	N/A
9/30/2023	605	99	15	49	N/A
6/30/2023	572	79	40	71	N/A
3/31/2023	556	65	34	76	N/A
12/31/2022	505	51	71	116	N/A
9/30/2022	498	41	62	137	N/A
6/30/2022	467	45	47	112	N/A
3/31/2022	440	35	47	81	N/A
12/31/2021	379	30	15	44	N/A
9/30/2021	394	27	31	61	N/A
6/30/2021	366	27	26	60	N/A
3/31/2021	342	26	42	81	N/A
12/31/2020	347	26	46	94	N/A
9/30/2020	357	27	-5	56	N/A
6/30/2020	370	28	-26	45	N/A
3/31/2020	403	32	-53	19	N/A
12/31/2019	395	31	-49	21	N/A
9/30/2019	371	35	-7	61	N/A
6/30/2019	385	37	-3	59	N/A
3/31/2019	375	34	N/A	N/A	N/A
12/31/2018	369	34	-44	21	N/A
9/30/2018	348	34	N/A	N/A	N/A
6/30/2018	351	34	-46	9	N/A
3/31/2018	344	32	N/A	N/A	N/A
12/31/2017	339	34	N/A	19	N/A
9/30/2017	344	33	N/A	N/A	N/A
6/30/2017	341	33	N/A	28	N/A
3/31/2017	338	29	N/A	N/A	N/A
12/31/2016	337	30	N/A	3	N/A
9/30/2016	343	30	N/A	N/A	N/A
6/30/2016	345	28	N/A	45	N/A
3/31/2016	336	28	N/A	N/A	N/A
12/31/2015	334	27	N/A	60	N/A
9/30/2015	321	25	N/A	N/A	N/A
6/30/2015	305	28	N/A	34	N/A
3/31/2015	314	32	N/A	N/A	N/A
12/31/2014	322	31	N/A	58	N/A
9/30/2014	320	34	N/A	N/A	N/A
6/30/2014	327	32	N/A	51	N/A
3/31/2014	321	32	N/A	N/A	N/A
12/31/2013	320	31	N/A	50	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if ATB's forecast earnings growth is above the savings rate (6.3%).

Earnings vs Market: Insufficient data to determine if ATB's earnings are forecast to grow faster than the RO market

High Growth Earnings: Insufficient data to determine if ATB's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if ATB's revenue is forecast to grow faster than the RO market.

High Growth Revenue: Insufficient data to determine if ATB's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if ATB's Return on Equity is forecast to be high in 3 years time

Antibiotice Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Recent updates

Upcoming dividend of RON0.083 per share

Second quarter 2024 earnings released

New major risk - Share price stability

Now 20% undervalued

Investor sentiment improves as stock rises 21%

Market Might Still Lack Some Conviction On Antibiotice S.A. (BVB:ATB) Even After 25% Share Price Boost

New minor risk - Share price stability

Investor sentiment improves as stock rises 17%

First quarter 2024 earnings released: EPS: RON0.056 (vs RON0.033 in 1Q 2023)

Full year 2023 earnings released: EPS: RON0.12 (vs RON0.077 in FY 2022)

Less than half of directors are independent

New minor risk - Dividend sustainability

Antibiotice S.A. (BVB:ATB) Looks Just Right With A 26% Price Jump

Antibiotice S.A. to Report Fiscal Year 2023 Results on Feb 28, 2024

Investor sentiment improves as stock rises 15%

We Think Antibiotice (BVB:ATB) Can Manage Its Debt With Ease

Third quarter 2023 earnings released: EPS: RON0.022 (vs RON0.009 in 3Q 2022)

Investor sentiment improves as stock rises 16%

Investor sentiment improves as stock rises 15%

These 4 Measures Indicate That Antibiotice (BVB:ATB) Is Using Debt Safely

Antibiotice S.A. to Report Fiscal Year 2022 Results on Feb 24, 2023

High number of new and inexperienced directors

High number of new and inexperienced directors

Third quarter 2021 earnings released: RON0.002 loss per share (vs RON0.002 loss in 3Q 2020)

Second quarter 2021 earnings released: EPS RON0.023 (vs RON0.022 in 2Q 2020)

Is Antibiotice (BVB:ATB) A Risky Investment?

First quarter 2021 earnings released: EPS RON0.006 (vs RON0.006 in 1Q 2020)

These 4 Measures Indicate That Antibiotice (BVB:ATB) Is Using Debt Extensively

Full year 2020 earnings released: EPS RON0.037 (vs RON0.046 in FY 2019)

Tread With Caution Around Antibiotice S.A.'s (BVB:ATB) 5.8% Dividend Yield

New 90-day high: RON0.52

Calculating The Intrinsic Value Of Antibiotice S.A. (BVB:ATB)

Are Antibiotice's (BVB:ATB) Statutory Earnings A Good Guide To Its Underlying Profitability?

Is Antibiotice (BVB:ATB) Using Too Much Debt?

New 90-day low: RON0.49

Third quarter 2020 earnings released: RON0.002 loss per share

New 90-day low: RON0.52

Upcoming Dividend of RON0.03 Per Share

Earnings released

New 90-day high - RON0.56

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies